The global tumor-specific antigen cancer immunotherapy industry is currently experiencing a rapid period of expansion, fueled by substantial progress in immunogenomics and a growing knowledge of the immune system's function in combating cancers. Predictions indicate a continued expansion in the next years, driven by therapeutic assessments demonstr